Which is the better buy?
2017 has been challenging for many UK pharmaceutical companies; with competition to pump out the most effective, cheapest and easiest to produce drugs at an all-time high, some UK Pharmas are feeling the pressure. However, after tough times often comes great opportunity.
This report looks at the two largest UK pharmaceutical companies, AstraZeneca and GlaxoSmithKline, and covers:
Why are two of the top 10 largest global drugmakers trading near 2017 lows? Will they fall further?
A comparison: Which stock is right for you.
What are the city analysts saying? Including 12-month target prices & Technical Analysis for each.
How to optimise potential returns on either stock.
Get your copy of this key report today.
Leveraged products involve a high level of risk and you can lose more than your initial outlay. They are not suitable for everyone so please ensure you understand the risks involved and if necessary please obtain professional advice. This report relates to CFDs and Spread Betting
Terms, Risk Warning & Disclaimer:
We operate on an execution only basis and this should not be taken as advice. If in doubt, please seek independent financial advice. Accendo Markets Ltd. 1 Alie Street, London, E1 8DE. Registered in England and Wales No. 6417051. Authorised and regulated by the Financial Conduct Authority No. 475285. This report has been issued and approved by Accendo Markets.
This guide is for information purposes only and Investment Superstore shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date. Investment Superstore does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this guide, or losses or damage you may incur doing so. There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.